PARP1 and head and neck squamous cell carcinoma: Similarly, studies have shown that the combination of the PARP inhibitor olaparib and DNA-PK inhibitor NU7441 with IR enhances HPV-negative HNSCC inhibition in both cell cultures and mice (103).